Virustatic / The Daughters of Mars

Virustatic, an innovator in antimicrobial textile coatings, developed a protein-based coating for facemasks and is expanding into women’s health with a coated tampon designed to prevent bacterial vaginosis. To advance their technology and meet regulatory requirements, Virustatic collaborated with iiCON.

Virustatic faced several key challenges:
• Effectiveness Testing: Verifying the antimicrobial properties of their facemask.
• Regulatory Compliance: Navigating complex regulatory requirements.
• Funding: Assisting with grant applications to support research and development.
• Experimental Design: Creating experiments to validate product claims.

iiCON provided crucial support in the following areas:
• Effectiveness Testing: Collaborated with the Liverpool School of Tropical Medicine (LSTM) to rigorously test the facemask, confirming its antimicrobial efficacy against pathogens.
• Regulatory Strategy: Assisted Virustatic in understanding and meeting regulatory standards for product approval, facilitating smoother market entry.
• Grant Applications: Helped prepare and submit grant applications, to secure necessary funding for further development.
• Experimental Design: Designed experiments to support the tampon’s claims of maintaining vaginal health and preventing bacterial vaginosis, providing robust evidence for regulatory approval.

The collaboration yielded significant results:
• Validated Technology: Effective antimicrobial facemask with proven performance.
• Regulatory Approval: Successful compliance with regulatory requirements.
• Funding: Funding applications submitted for continued innovation.
• Validated Claims: Strong evidence supporting the tampon’s health benefits.

The partnership between Virustatic/Daughters of Mars and iiCON highlights the impact of strategic support in advancing innovative technologies and addressing critical health issues.

“Partnering with iiCON was pivotal for us. Their expertise in testing, regulatory strategy, and grant applications was instrumental in bringing our innovative antimicrobial technology to market. Their support not only validated our products but also enabled us to secure the necessary funding and approvals to address critical health challenges effectively.” Lucy Hope, Director of Virustatic.